BioSpace News Archive

Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, announced it has added eleven scientists to its manufacturing, preclinical and clinical teams, a major milestone in the company’s strategy to build a beginning-to-end internal-external supply model led by its pioneering cell and gene therapy expertise.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2021 financial results and Company update after the market closes on Tuesday, May 11, 2021.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 9 newly-hired employees options to purchase an aggregate of 197,200 shares of Akebia’s common stock on April 30, 2021, as inducements material to each such employee’s entering into employment with Akebia.

Cryoport, Inc., a global leader in temperature-controlled supply chain solutions for the life sciences industry, announced financial results for the three-month period ended March 31, 2021.

Invitae Corporation, a leading medical genetics company, announced financial and operating results for the first quarter ended March 31, 2021 signaling continued momentum into 2021.

Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2021.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the Sidoti & Company LLC Virtual Microcap Conference being held May 19-20, 2021.

Successful listing on TSXV advances Small Pharma’s bold vision to revolutionize the treatment of patients with mental health conditions through psychedelic-assisted therapies

Paragon 28, Inc. unveils the highly anticipated MAVEN™ PSI System, a platform technology thoughtfully designed to expedite accurate positioning of the APEX 3D™ Total Ankle Replacement System.

Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC